MedTrace Logo

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

NCT06975293 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2026-04-21

No results posted yet for this study

Summary

This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors.

The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).

Conditions

  • Solid Tumor
  • Sarcoma
  • Leiomyosarcoma
  • Dedifferentiated Liposarcoma

Interventions

COMBINATION_PRODUCT

STC-15 in combination with toripalimab

STC-15 in combination with toripalimab in 21-day cycles

DRUG

STC-15 monotherapy

STC-15 monotherapy in 21-day cycles

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    collaborator INDUSTRY

  • STORM Therapeutics LTD

    lead INDUSTRY

Principal Investigators

  • Sandra Tong, MD · Storm Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2027-12-29
Completion
2028-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06975293 on ClinicalTrials.gov